Drug intelligence / Profile preview

novel miRNA inhibitor N2

Development stage: Preclinical
Lead developer: University of Bradford
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

Novel miRNA inhibitor N2 is an experimental antisense oligonucleotide designed to target and inhibit a specific, unnamed microRNA (miRNA) identified in exosomes derived from cord blood stem cells (CBSC-EV). Research presented at the AACR 2024 annual meeting demonstrated that N2, when used in conjunction with CBSC-EVs, modulates gene expression within cytokine-mediated signaling and interaction pathways in malignant melanoma cells. This inhibition appears to enhance the apoptotic and anti-tumor effects of the exosomes while sparing healthy cells, suggesting a potential role for such inhibitors in future cancer immunotherapy and genetic medicine.

Other names: novel miRNA inhibitor N2

Beyond the preview

Go deeper on novel miRNA inhibitor N2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on novel miRNA inhibitor N2.

Explore the full profile